New drug combo could offer hope for tough Crohn's cases
NCT ID NCT07510191
First seen Apr 08, 2026 · Last updated May 13, 2026 · Updated 6 times
Summary
This study tests whether adding a low-dose of upadacitinib to a standard TNF inhibitor works better than increasing the TNF inhibitor dose alone for people with moderate-to-severe Crohn's disease who aren't getting enough relief. About 312 adults will be randomly assigned to one of two treatment groups and followed for at least 14 weeks. The goal is to see if the combination leads to more people achieving remission with acceptable safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE (CD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Sixth Affiliated Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.